NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
Clinical Trials
10 trialsNCT04039230 2026-03-16
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Massachusetts General Hospital
Phase 1/2 Active not recruiting
NCT07461454 2026-03-10
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Not yet recruiting
NCT04468061 2026-02-27
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06100874 2026-02-24
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04639986 2026-02-09
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Gilead Sciences
Phase 3 Active not recruiting
NCT07367178 2026-01-28
SATROPIN
MedSIR
Phase 2 Not yet recruiting
NCT07368543 2026-01-28
STORM
Fudan University
Phase 2 Not yet recruiting
NCT04448886 2026-01-15
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06263543 2025-12-26
SERIES
Baptist Health South Florida
Phase 2 Recruiting